Eli Lilly Shares Surge as Analysts Boost Ratings
Veröffentlicht: 15.10.2025 um 11:45 Uhr, Redaktion boerse-global.de
Pharmaceutical giant Eli Lilly is capturing renewed attention from market experts, with two prominent research firms simultaneously upgrading their assessments of the diabetes and weight management specialist on October 14. Erste Group Bank elevated its rating from “Hold” to “Buy,” while Seeking Alpha followed with similar positive sentiment. This coordinated optimism stems from the company’s robust product pipeline, market dominance, and the continuing surge in demand for weight-loss medications.
The company’s blockbuster treatments Mounjaro and Zepbound have established a commanding position within a market segment projected to expand to at least $100 billion by the decade’s end. This technological leadership, particularly with the multi-targeting tirzepatide molecule found in both medications, is viewed as superior to single-mechanism competitor products, potentially securing additional market share in this rapidly growing... Read more...
Disclaimer zu unseren Artikeln: Keine Anlageberatung, keine Kauf oder Verkaufsempfehlung. Angaben zu Kursen, Unternehmen und Märkten ohne Gewähr; Änderungen jederzeit möglich. Börsengeschäfte können zu hohen Verlusten führen. Unsere Beiträge werden ganz oder teilweise automatisiert mit Unterstützung von AI erstellt und geprüft.
